HKSE · 8372.HK
Grand Brilliance Group Holdings Limited
HK$0.17+HK$0.00 (+0.61%)
Grand Brilliance Group Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 7.78% below the high.
Loading market information…
HKSE · 0574.HK · HKD
Stock price, dividends, earnings
Quote as of Jun 30, 2026, 07:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Pa Shun International Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 77.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Pa Shun International Holdings Limited’s forward annual dividend is HK$0.27 per share, paid monthly. The forward yield is 1,517.8% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pa Shun International Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, and other medical institutions in rural areas. It also sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is headquartered in Wan Chai, Hong Kong. Pa Shun International Holdings Limited operates as a subsidiary of Praise Treasure Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:51 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$0.17+HK$0.00 (+0.61%)
Grand Brilliance Group Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 7.78% below the high.
HK$0.21+HK$0.01 (+5.5%)
Republic Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 24.64% below the high.
HK$0.11+HK$0.01 (+7.92%)
Wanjia Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 47.85% below the high.
HK$0.19-HK$0.02 (-10.38%)
Kelfred Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 65.45% below the high.
HK$0.11-HK$0.01 (-5.88%)
Raily Aesthetic Medicine International Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
HK$0.15-HK$0.00 (-0.65%)
Medicskin Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 24.0% below the high.
HK$0.07-HK$0.00 (-1.35%)
China Healthwise Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
HK$0.32HK$0.00 (0.0%)
Qianhai Health Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 77.5% below the high.
